We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Hold Lifted, CytRx to Resume ALS Trials With New Protocol
FDA Hold Lifted, CytRx to Resume ALS Trials With New Protocol
December 9, 2009
CytRx will be allowed to resume clinical trials of its oral drug arimoclomol to treat amyotrophic lateral sclerosis (ALS) because the FDA has accepted its revision of a study protocol.